RxSight (RXST) shares fell over 30% during Tuesday after-hours trading after it reported preliminary Q2 revenue of $33.6 million, down from $34.9 million a year earlier.
Analysts polled by FactSet expect $39.8 million.
The company cut its full-year 2025 revenue guidance to $120 million to $130 million from $160 million to $175 million earlier. Analysts surveyed by FactSet expect $167.6 million.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。